Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nantes University Hospital
With
French Innovative Leukemia Organisation
Hoffmann-La Roche
Superiority of HDT with autologous stem cell transplantation (ASCT) in the upfront treatment of poor-risk DLBCL remains an option for intermediate-high (IH) or high IPI young adults. We updated results of the prospective trial Goelams 074 to evaluate long-term efficacy and toxicity in 42 patients who underwent HDT with ASCT.
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 to 60 y.o
Aggressive Large B-Cell Lymphoma (CD20+)
Ann Arbor stage III, IV
IH or high adjusted IPI
signed inform consent
You may not be if
Age \< 18 ou \> 60 y.o
other type of lymphoma
serology VIH +
other neoplasms apart from basal cell carcinoma or situ carcinoma
Clareo Health | High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma
